The Jakarta Post
State pharmaceutical company PT Bio Farma plans to invest Rp 500 billion to construct a pharmaceutical plant to produce derivative products from blood plasma including Albumin and Factor IX.
Bio Farma public relations chief Tedy Herawan on Thursday said the plant would be the first of its kind in Indonesia and would aim to supply growing domestic demand, which mostly sees imports from the Netherlands.
“Albumin, for example, is very important for thalassemia patients. But these patient must pay Rp 2 million [US$222] per package. Producing albumin domestically will help these consumers with lower prices,” Teddy said.
Albumin is commonly administered for a medical conditions where levels of albumin in blood serum are abnormally low, as well as in therapeutic plasma exchanges and cardiothoracic surgery.
Factor IX is a protein substance in blood plasma that is ...